Comparative Pharmacology
Head-to-head clinical analysis: OZOBAX versus RELA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OZOBAX versus RELA.
OZOBAX vs RELA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
OZOBAX (carisoprodol) is a centrally acting skeletal muscle relaxant that does not directly relax skeletal muscle. Its mechanism of action is thought to be related to its sedative properties and its metabolite, meprobamate, which has anxiolytic and sedative effects. Carisoprodol acts as a GABA-A receptor agonist and may also inhibit interneuronal activity in the spinal cord and reticular formation.
RELA (Carisoprodol) is a centrally acting muscle relaxant that modulates GABA-A receptor activity and blocks interneuronal activity in the descending reticular formation and spinal cord, resulting in muscle relaxation without directly affecting the neuromuscular junction. Its metabolite, meprobamate, contributes to anxiolytic and sedative effects.
OZOBAX (baclofen) oral: Initial 5 mg three times daily, may increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg four times daily). Intrathecal: Test dose 50-100 mcg, then continuous infusion via pump 22-900 mcg/day.
Adults: 250-350 mg orally 3-4 times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 12-15 hours in adults with normal renal function. This supports twice-daily dosing in most patients.
Terminal elimination half-life approximately 20–30 hours; prolonged in elderly and renal impairment
Primarily renal excretion of unchanged drug (approximately 70-80% of the dose) with minor biliary/fecal elimination (10-15%).
Primarily renal excretion of unchanged drug and metabolites; 70% to 80% eliminated via urine, remainder biliary/fecal
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant